108 posters,  9 topics,  397 authors,  84 institutions

ePostersLive® by SciGen® Technologies S.A. All rights reserved.

Poster 109
Percutaneous Microwave Lung Tumor Ablation: A Single Center Mid-Term Experience

Primary tabs


No votes yet


105 reads

Percutaneous Microwave Lung Tumor Ablation: A Single Center Mid-Term Experience


To evaluate overall survival, disease free progression, and tumor control following percutaneous microwave ablation of primary and metastatic lung tumors performed at a single institution.


•Under IRB exemption, our institution’s MW ablation database was retrospectively reviewed for all percutaneous microwave lung ablations performed between August 2011 and August 2016.
•All ablations performed using a high-powered gas-cooled microwave system (Neuwave Medical, Madison WI).
•Patients divided into two study groups for further analysis: a) primary lung tumors and b) lung metastases.
•Tumor and ablation parameters were recorded and follow-up imaging was reviewed for local and distant tumor progression.
•Complications were recorded and categorized according to the SIR classification system.
•Overall (OS) and progression-free survival (PFS) were calculated via a Kaplan-Meyer analysis. 

Procedural Details

•Median number of ablation probes used: 1
•Mean treatment power: 63 W
•Mean ablation time: 7 minutes
•Technical success rate: 100%


•The most commonly encountered complication was pneumothorax, occurring in 76% (29/38) of sessions. Of that group, chest tubes were only required in 17% (5/29) of cases, for an overall rate of 13% (5/38) in all patients undergoing lung MW. All chest tubes removed within 2 days.
•There were only two major complications: a single case of recurrent pleural effusion requiring serial thoracenteses, and a single case of aspergilloma development within an ablation cavity requiring oral antifungal therapy in a radiation failure patient.
•No broncho-pleural fistulas in this study.


•Median imaging follow-up:

       23 months in metastatic group

       17 months in primary lung group

Local Control

•Local tumor progression:

        19.1% in lung primary group (4/21)*

        19.2% in metastases group (5/26)

•Distant tumor progression:

        21.4% in both groups*


*Note that a large number of primary lung malignancy patients had previously undergone surgical/SBRT or other treatment (9/21) and were not treated with MW de novo



•Overall survival and progression-free survival are shown in Figures 1 and 2, respectively.
•Our institutional results demonstrate that high-powered microwave can be safely utilized in the lung, with a favorable complication profile favorable
•Our study is limited by a large number of primary lung tumor ablations performed as salvage therapy. Despite this limitation, MW ablation remains an effective modality for treatment of primary and metastatic pulmonary malignancy
Enter Poster ID (e.gGoNextPreviousCurrent